Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.66, demonstrating a +1.39% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 1.02%, while the tech-heavy Nasdaq depreciated by 0.02%.
The stock of biotechnology company has fallen by 9.07% in the past month, lagging the Medical sector's gain of 1.01% and the S&P 500's gain of 0.67%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. The company is expected to report EPS of -$0.24, up 33.33% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $8.42 million, showing a 62.57% escalation compared to the year-ago quarter.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$0.93 per share and revenue of $42.82 million. These results would represent year-over-year changes of +35.42% and -42.66%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.72% downward. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 98, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Recursion Pharmaceuticals, Inc. (RXRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).